Medicon Valley Alliance and Fareva would like to welcome you to a Good Morning Meeting 28th of April 2026.
Embarking on the journey from drug discovery to commercialization is fraught with obstacles, from unexpected issues in chemical development to challenges in drug product manufacturing. Not only is developing a new drug expensive, but an extraordinarily lengthy and complex process. From the initial stages of drug discovery, clinical trials and regulatory approvals to pre-and post-launch strategizing and commercialization, pharmaceutical companies face numerous obstacles and uncertainties. As clinical phases progress, the demands escalate, necessitating a comprehensive approach for a successful launch. At FAREVA, we leverage our extensive experience to tackle these challenges, continually evolving our strategies to deliver customized solutions for our clients. Join us as we share valuable insights and real case studies, providing a deeper understanding of our expertise in the upcoming talks.
Date: Tuesday 28th of April 2026
Time: 8:30 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Hub 2
Program
| 8:30 | Networking, registration and light breakfast |
| 9:00 | Welcome and introduction to Medicon Valley Alliance David Munis Zepernick, Director, Member Engagement & Communication, Medicon Valley Alliance |
| 9:05 | Welcome and Introduction to FAREVA Richa Foster-Jones, Business Development Sales Director DP, FAREVA Stefan van Thiel, Commercial Director API – CDMO & Generic APIs, FAREVA |
| 9:15 | Innovative Approach to API Process Development Thomas Pfeuffer, PhD, Business Development Manager API, FAREVA |
| 9:45 | Long Acting Injection (LAI) sterile technical development: Challenges from Clinical batches to routine manufacturing Philippe Rampignon, VP Pharmaceutical Development, FAREVA |
| 10:00 | Mini Tablet a technical alternative oral solid doses Philippe Rampignon, VP Pharmaceutical Development, FAREVA |
| 10:15 | Q & A |
| 10:30 | Networking |
| 11:00 | End of Good Morning Meeting |
Speakers
 |
Richa Foster-Jones, Business Development Director DP, FAREVA
Richa Foster-Jones is the Area Sales Director at FAREVA for Drug Product (DP) services covering UK, IR & Nordics. She has a good mix of science and business background with master’s in biotechnology from India and MBA from Dundee, Scotland which enables her to understand and communicate technical & business aspects of the solutions to her clients and partners. |
 |
Philippe Rampignon, Vice President R&D Pharma, FAREVA
Philippe Rampignon VP Pharma R&D, joined Fareva 5 years ago, leading the Pharmaceutical Development and Tech transfers activities in BU Pharma. After earning a PharmD with a specialization in industrialization processes, he built his career in both local and global organizations within NPI/MSAT structure at Schering-Plough, Abbott, GSK Pharma, Guerbet, GSK, and Sanofi. Throughout his journey, he developed expertise as a Subject Matter Expert, and various roles in MSAT and Pharmaceutical development activities across global pharma organizations. |
 |
Stefan van Thiel, Commercial Director API – CDMO & Generic APIs, FAREVA
Stefan van Thiel is Commercial Director API – CDMO & Generic APIs at FAREVA, where he leads the global commercial activities for API CDMO services and generic APIs. In addition, he plays a key role in developing and driving FAREVA’s CDMO strategy and expanding its commercial activities in the small molecule API space. He brings extensive international experience in pharmaceutical business development, strategic account management and commercial leadership across key markets including Europe, the US, Japan, India, Brazil and China. In his role, he works closely with customers and internal teams to develop tailored solutions, support complex outsourcing projects and build long-term strategic partnerships. |
 |
Thomas Pfeuffer, PhD, Business Development Manager API, FAREVA
Dr. Thomas Pfeuffer (PhD) is Business Development Manager API at FAREVA Excella. After receiving his degree in pharmaceutical chemistry from the university of Wuerzburg, he started working for Excella GmbH & Co KG in 2010. There, he was responsible for cleaning- and process validation, giving him a good insight into development, chemical production and GMP procedures. Later he was accountable for project management API for CDMO customers before moving to the sales team. The experience gained from various positions helps him to understand the customers’ needs and enables him to develop tailor-made solutions. |
| Organized by | In collaboration with |
 |
 |